These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1028 related articles for article (PubMed ID: 33312177)

  • 1. Immune Dysfunctions and Immune-Based Therapeutic Interventions in Chronic Lymphocytic Leukemia.
    Griggio V; Perutelli F; Salvetti C; Boccellato E; Boccadoro M; Vitale C; Coscia M
    Front Immunol; 2020; 11():594556. PubMed ID: 33312177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NK Cells in Chronic Lymphocytic Leukemia and Their Therapeutic Implications.
    Sportoletti P; De Falco F; Del Papa B; Baldoni S; Guarente V; Marra A; Dorillo E; Rompietti C; Adamo FM; Ruggeri L; Di Ianni M; Rosati E
    Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34206399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel Therapies in Chronic Lymphocytic Leukemia: A Rapidly Changing Landscape.
    Iovino L; Shadman M
    Curr Treat Options Oncol; 2020 Mar; 21(4):24. PubMed ID: 32170458
    [TBL] [Abstract][Full Text] [Related]  

  • 4. T Cells in Chronic Lymphocytic Leukemia: A Two-Edged Sword.
    Vlachonikola E; Stamatopoulos K; Chatzidimitriou A
    Front Immunol; 2020; 11():612244. PubMed ID: 33552073
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cellular immune therapy for chronic lymphocytic leukemia.
    Kater AP; van Oers MH; Kipps TJ
    Blood; 2007 Oct; 110(8):2811-8. PubMed ID: 17638850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Engaging Cytotoxic T and NK Cells for Immunotherapy in Chronic Lymphocytic Leukemia.
    Hofland T; Eldering E; Kater AP; Tonino SH
    Int J Mol Sci; 2019 Sep; 20(17):. PubMed ID: 31484424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment.
    Hallek M
    Am J Hematol; 2019 Nov; 94(11):1266-1287. PubMed ID: 31364186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chimeric Antigen Receptor T Cells in Chronic Lymphocytic Leukemia: Are We Any Closer to a Cure?
    Rhodes JM; Schuster SJ
    Cancer J; 2019; 25(6):436-441. PubMed ID: 31764125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in chimeric antigen receptor immunotherapy for chronic lymphocytic leukemia.
    Riches JC; Gribben JG
    Discov Med; 2013 Dec; 16(90):295-302. PubMed ID: 24333409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune Response Dysfunction in Chronic Lymphocytic Leukemia: Dissecting Molecular Mechanisms and Microenvironmental Conditions.
    Arruga F; Gyau BB; Iannello A; Vitale N; Vaisitti T; Deaglio S
    Int J Mol Sci; 2020 Mar; 21(5):. PubMed ID: 32155826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improving therapy of chronic lymphocytic leukemia with chimeric antigen receptor T cells.
    Fraietta JA; Schwab RD; Maus MV
    Semin Oncol; 2016 Apr; 43(2):291-9. PubMed ID: 27040708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapeutic Strategies in Chronic Lymphocytic Leukemia: Advances and Challenges.
    Perutelli F; Jones R; Griggio V; Vitale C; Coscia M
    Front Oncol; 2022; 12():837531. PubMed ID: 35265527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunomodulation and immune reconstitution in chronic lymphocytic leukemia.
    Riches JC; Gribben JG
    Semin Hematol; 2014 Jul; 51(3):228-34. PubMed ID: 25048786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccine- and immune-based therapy in chronic lymphocytic leukemia.
    Le Dieu R; Gribben J
    Semin Oncol; 2006 Apr; 33(2):220-9. PubMed ID: 16616069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tailored Treatment Strategies for Chronic Lymphocytic Leukemia in a Rapidly Changing Era.
    Brander D; Islam P; Barrientos JC
    Am Soc Clin Oncol Educ Book; 2019 Jan; 39():487-498. PubMed ID: 31099686
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HLA ligandome analysis identifies the underlying specificities of spontaneous antileukemia immune responses in chronic lymphocytic leukemia (CLL).
    Kowalewski DJ; Schuster H; Backert L; Berlin C; Kahn S; Kanz L; Salih HR; Rammensee HG; Stevanovic S; Stickel JS
    Proc Natl Acad Sci U S A; 2015 Jan; 112(2):E166-75. PubMed ID: 25548167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ibrutinib for improved chimeric antigen receptor T-cell production for chronic lymphocytic leukemia patients.
    Fan F; Yoo HJ; Stock S; Wang L; Liu Y; Schubert ML; Wang S; Neuber B; Hückelhoven-Krauss A; Gern U; Schmitt A; Müller-Tidow C; Dreger P; Schmitt M; Sellner L
    Int J Cancer; 2021 Jan; 148(2):419-428. PubMed ID: 32683672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures.
    Hallek M; Al-Sawaf O
    Am J Hematol; 2021 Dec; 96(12):1679-1705. PubMed ID: 34625994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T cells in chronic lymphocytic leukemia display dysregulated expression of immune checkpoints and activation markers.
    Palma M; Gentilcore G; Heimersson K; Mozaffari F; Näsman-Glaser B; Young E; Rosenquist R; Hansson L; Österborg A; Mellstedt H
    Haematologica; 2017 Mar; 102(3):562-572. PubMed ID: 27927767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New insights into hematopoietic stem cell transplantation for chronic lymphocytic leukemia: a 2015 perspective.
    McClanahan F; Gribben J
    Clin Adv Hematol Oncol; 2015 Sep; 13(9):586-94. PubMed ID: 26452190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 52.